FDA is looking into hematology risks after patients take Bluebird’s Skysona gene therapynews2024-11-27T19:44:30+00:00November 27th, 2024|Endpoints News|
Updated: Roche buys out CAR-T partner Poseida for $1B upfrontnews2024-11-26T11:41:03+00:00November 26th, 2024|Endpoints News|
Patient dies in Neurogene’s Rett syndrome studynews2024-11-21T22:30:12+00:00November 21st, 2024|Endpoints News|
#ACR24: Bristol Myers takes on autoimmune diseases with cell therapy; New data from Cabaletta and Kyvernanews2024-11-19T15:52:02+00:00November 19th, 2024|Endpoints News|
Rocket shares promising long-term results from rare heart disease gene therapy in small studynews2024-11-18T20:31:08+00:00November 18th, 2024|Endpoints News|
Neurogene patient had life-threatening side effect in Rett syndrome studynews2024-11-18T19:55:48+00:00November 18th, 2024|Endpoints News|
CSL Behring will close California office as part of shrinking ex vivo worknews2024-11-18T19:34:37+00:00November 18th, 2024|Endpoints News|
FDA offers more guidance on developing cell and gene therapiesnews2024-11-18T19:21:10+00:00November 18th, 2024|Endpoints News|
Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis assetnews2024-11-18T09:09:43+00:00November 18th, 2024|Endpoints News|
Gilead to close Philadelphia and Seattle offices, make job cutsnews2024-11-14T20:30:36+00:00November 14th, 2024|Endpoints News|
